The FDA has approved Gallium 68 PSMA-11 for patients suspected of having prostate cancer metastasis who are potentially treatable with surgery or radiation therapy. The approval also covers patients with suspected prostate cancer recurrence, given their abnormal prostate-specific antigen (PSA) levels. An intravenous radioactive diagnostic agent, the drug is the first compound supporting positron emission…